Searched for
BIOCON BIOLOGICS ACQUISITION
The alchemist of Bengaluru: Kiran Mazumdar-Shaw began from a garageKiran Mazumdar-Shaw has named her niece Claire Mazumdar as successor, setting up a gradual leadership transition at Biocon. A pioneer who b...- Biocon Biologics gets global rights for biosimilar AdalimumabBiocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full control over ...
- Biocon shares jump 3% to hit new 52-week high on $4.5 billion Biologics IPO, merger reviewBiocon shares hit a new 52-week high after the company confirmed it is evaluating a potential merger of Biocon Biologics with the parent en...
- Biocon considers merging Biocon Biologics in $4.5 billion deal; IPO and share swap options under reviewBiocon is exploring merging its biosimilars arm, Biocon Biologics, with itself, potentially valuing the unit at $4.5 billion. The company i...
- Biocon shares in focus after Q3 PAT drops 96% YoY, 1.5% additional stake acquisition in subsidiaryBiocon share price: Biocon reported a 96% year-on-year (YoY) decline in net profit, which fell to Rs 25 crore in Q3FY25. In comparison, the...
- Biocon Biologics looks to trim $300 million debt in 1 yearBiocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in d...
- Biocon Biologics is planning to raise $950 million through overseas bondsBiocon Biologics plans to raise $950 million through overseas bond sales to refinance a significant portion of its $1.2-billion debt from a...
- Biocon Biologics to raise debt of Rs 4,500 crore for Viatris PayoutBiocon Biologics plans to raise ₹4,500 crore with HSBC and MUFG's aid for a $175 million Aflibercept option. Previous funding by Kotak and ...
- Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year agoThe company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded...
- Biocon Biologics completes integration of Viatris' Europe biosimilar businessBiocon Biologics on Thursday said it has completed the integration of the acquired biosimilar business from Viatris Inc in 31 European coun...
- Eris Lifesciences acquires Biocon Biologics' nephro, derma units for Rs 366 croreEris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...
- Competition Commission of India clears Kotak-Biocon Biologics dealThe investment will help Biocon Biologics' acquisition of the biosimilars business of its partner Viatris.
- Biocon Biologics launches biosimilar adalimumab in USAdalimumab is used to treat certain inflammatory diseases like rheumatoid arthritis. Humira contributed $21.2 billion in sales to AbbVie fo...
- Kotak fund invests Rs 1070 crore in BioconEshwar Karra, CEO – Kotak Special Situations Fund at Kotak Investment Advisors said, We are delighted to partner with Biocon and this acqui...
- Biocon Biologics has comprehensive plan to integrate Viatris business: Shreehas Tambe, Biocon Biologics"There are several other discussions that we have been having with private equity investors who are interested in making an investment in B...
- Biocon Biologics appoints Shreehas Tambe as MD & CEOTambe has been with Biocon since 1997 and has held diverse leadership and operational roles. Over the past 25 years, he has helped build an...
- Biocon completes $3.34 billion acquisition of Viatris's biosimilar businessTo fund the upfront payment, Biocon Biologics has secured $1.2 billion of Sustainability Linked Loan (SLL). The balance has been funded thr...
- Biocon Biologics secures regulatory approvals for acquisition of Viatris' biosimilar businessThe transaction with US-based Viatris required regulatory approvals from the Reserve Bank of India, Competition Commission of India and the...
- Biocon Biologics expects big gains from integration of Viatris business, SII dealBiocon Biologics in March entered into a definitive agreement to acquire Viatris' biosimilars assets for $3.34 billion. It will pay Viatris...
- CCI clears Serum Institute Life Sciences-Biocon Biologics dealOnce the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to th...
Load More
